New hope for young cancer patients: drug combo targets relapsed solid tumors
NCT ID NCT06761417
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to previous treatments. The goal is to see if this regimen can shrink tumors or stop them from growing. Participants will receive up to 6 cycles of treatment and be closely monitored for side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 49 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 24 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Main inclusion Criteria: 1. The patient fully understands this study, voluntarily participates and signs the informed consent form (ICF). 2. Age: children (6 - 12 years old), adolescents (13 - 18 years old) and young adults (19 - 24 years old) (CAYA). The expected survival time is \> 3 months. 3. Diagnosed with relapsed and refractory solid tumors by histopathology, and it is one of the following subtypes: (1) bone and soft tissue tumors; (2) neuroblastoma; (3) other types of solid tumors that the investigator deems eligible for enrollment. 4. There must be measurable tumor lesions by CT, enhanced CT, PET/CT or MRI. 5. Karnofsky score \> 50; ECOG score ≤ 2. 6. Bone marrow function: neutrophil count \> 1.5 × 10⁹/L, platelet count \> 75 × 10⁹/L, hemoglobin ≥ 80 g/L. 7. Liver and kidney function: serum creatinine ≤ 1.5 times the upper limit of normal value; AST and ALT \< 2.5 times the upper limit of normal value (for patients with liver invasion \< 5 times the upper limit of normal value); total bilirubin \< 1.5 times the upper limit of normal value (for patients with liver invasion \< 3 times the upper limit of normal value). 8. No history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, no history of clinically severe pericardial disease, or no electrocardiogram evidence of acute ischemic or active conduction system abnormality within 6 months before recruitment. Main exclusion Criteria: 1. Patients with known hypersensitivity to any component of the study drugs. 2. Patients with other malignant tumors that are not under control (except for basal cell carcinoma of the skin, in-situ breast/cervical cancer, and other malignant tumors that have been effectively controlled without treatment in the past five years). 3. Pregnant, lactating women and women of childbearing age who are unwilling to take contraceptive measures. 4. Other situations judged by the investigator as not suitable for participating in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adolescents are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a local anesthetic injection curb Kids' pain after tonsil removal?
- Two ways to rebuild a Child's bone: which holds up?
- Can a pill shrink Hard-to-Treat ovarian tumors?
- Gene tests could untangle the 150 names for bone and soft tissue tumors
- Experimental infusion drug tested against recurrent nasopharyngeal cancer
- Can a pill target tumors with the PIK3CA-H1047R mutation?